Retatrutide Anhedonia, Mood and Libido: What the Evidence Shows

No retatrutide trial has reported a mood, anxiety, depression or libido result in its registry tables, journal abstracts or Lilly releases, so nobody can give you a rate for retatrutide anhedonia. The closest evidence covers the drug class: in January 2026 the FDA pooled 91 placebo-controlled GLP-1 trials with 107,910 people and found no rise in depression, anxiety or suicidal thoughts. The flat, joyless feeling people describe on forums hasn't been measured in any trial, and that's a different thing from it not happening.

As of October 2026, retatrutide is investigational: Lilly says it "has not been reviewed or approved by the FDA or any regulatory agency in the world", so there's no label with a mood section to read. Where its data runs out, we use tirzepatide and semaglutide data and call it class evidence.

Does retatrutide affect mood?

Nobody knows yet. The public retatrutide record on mood fits in four rows.

Two details change how to read that table. The Phase 2 registry tables list non-serious events only if they reached 5% of at least one group, and with 23 to 70 people per group, a problem hitting 1 person in a group wouldn't show up. And the Phase 2 obesity trial excluded anyone with "a major problem with depression or other mental illness within the last 2 years", per its ClinicalTrials.gov listing. TRANSCEND-T2D-1 excluded anyone who had ever attempted suicide.

So if you've had depression recently, the retatrutide trials weren't set up to tell you anything about your risk.

What people describe as retatrutide anhedonia

Anhedonia means losing interest or pleasure in things you used to enjoy. The National Institute of Mental Health lists it as one of the two core symptoms of depression, next to low mood, but having it doesn't by itself mean you're depressed.

In online threads the word gets used loosely: food stops being interesting, then music, hobbies or sex feel muted too, and the feeling is a flat "meh" more than sadness. Other posts describe the opposite, with "food noise" going quiet and feeling calmer. We haven't counted these, they aren't a study, and people who feel fine rarely post about it.

No trial has checked whether the feeling follows dose, timing or a dose increase (the trial steps are on the retatrutide dosage page). If you came to retatrutide from tirzepatide or semaglutide (see switching from tirzepatide), a flat feeling isn't automatically about retatrutide.

Why would retatrutide anhedonia happen?

There's a plausible mechanism, with no retatrutide data behind it. GLP-1, one of the three hormones retatrutide mimics, also works in the brain. The FDA describes it as acting "in parts of the brain that control appetite and food intake".

A 2014 brain-scan study of 48 adults, published in Diabetes, tested that in people. In those with obesity, with or without type 2 diabetes, an intravenous GLP-1 drug (exenatide) damped how strongly reward and appetite areas such as the insula and amygdala lit up at pictures of food, and blocking the GLP-1 receptor first largely cancelled the effect. In a 2025 JAMA Psychiatry trial of 48 adults with alcohol use disorder, low-dose semaglutide cut craving and how much people drank in a lab session. So the class affects reward beyond food, and the page on retatrutide and alcohol covers what that means for drinking.

The anhedonia theory follows: if the drug turns down wanting food and alcohol, maybe it turns down wanting in general. No trial has tested it with a pleasure or motivation scale.

Tirzepatide shares the GIP signal; glucagon is retatrutide's addition. We couldn't find a published human study of what glucagon-receptor drugs do to mood, so tirzepatide data can only take you so far.

Our read: the same brain effect that quiets food noise is the likeliest source of the flat feeling when it shows up, and one mechanism would explain why reports split into "calmer" and "numb".

Can reta cause anxiety or depression?

For the drug class, the best evidence says no. In January 2026 the FDA asked for the suicidal-thoughts warning to come off the Saxenda, Wegovy and Zepbound labels. Its meta-analysis of 91 placebo-controlled trials, 60,338 people on a GLP-1 drug and 47,572 on placebo, found no increased risk of suicidal thoughts or behavior, or of anxiety, depression, irritability or psychosis.

The two drugs closest to retatrutide each have a post hoc analysis of their weight trials, scored with the PHQ-9 depression questionnaire (0 to 27, higher is worse). This is class evidence, not retatrutide data.

In plain numbers, anxiety came up in about 1 in 67 people on tirzepatide and about 1 in 28 on placebo. People on tirzepatide were also less likely to slide into a worse depression category (18.2% vs 24.3%). Both sets of authors say the drop in depression scores was too small to be clinically meaningful.

One class result points the other way. In the Wegovy label's 68-week trial in teenagers with obesity (133 on semaglutide, 67 on placebo), anxiety was reported in 4% on semaglutide against 2% on placebo. That's a small group and a different age, but it's a reminder that adult averages don't cover everyone.

Three limits apply. Both analyses left out people with major depression in the past 2 years, a moderately severe PHQ-9 score or a past suicide attempt. Both were written with drugmaker authors (Novo Nordisk for semaglutide, Lilly for tirzepatide). And the tirzepatide authors call for more trials in people with managed conditions such as depression, bipolar disorder or anxiety.

Our read: if you have no psychiatric history, the class data points away from a real anxiety or depression risk, so new anxiety on retatrutide deserves a look at the body causes below before anyone blames brain chemistry.

Does retatrutide lower libido?

Erectile dysfunction in 2 of 36 men on the lowest dose, 1 mg, is the only sexual-function entry in retatrutide's Phase 2 registry tables. No man on placebo or on 4, 8 or 12 mg had it, and no trial has reported a libido result. Numbers that small, with no dose pattern, look more like chance than a drug effect.

The class signal is small at most. A sex-drive problem was reported in 12 of 2,806 people on tirzepatide (0.43%) against 2 of 1,250 on placebo (0.16%); the paper's "sexual desire disorders" group doesn't say whether drive went up or down. Neither the Zepbound label (revised August 2026) nor the Wegovy label (revised June 2026) lists low libido, sexual problems or depression among its side effects.

The NHS lists the main causes of a low sex drive, and most have nothing to do with a weight drug: stress, anxiety or depression, relationship problems, some medicines, and long-term conditions such as diabetes. If you're worn out as well, see whether retatrutide makes you tired. The NHS says to see a GP if you think a medicine is affecting your sex drive.

Rule out the body causes first

A mood change on retatrutide can have a physical cause you can check. NIMH's list of depression symptoms includes tiredness, appetite changes, weight changes, digestive problems and problems with sexual desire, which also describes a normal escalation month on retatrutide. That overlap makes self-diagnosis unreliable in both directions.

Poor sleep leaves anyone short-fused, and it has its own page on retatrutide insomnia.

What's in the vial is the other thing to rule out. Lilly says products sold as retatrutide outside its trials may hold too much or too little active ingredient, or the wrong one. In September 2026, Australia's TGA reported testing a vial sold as retatrutide that contained no retatrutide but did contain undeclared semaglutide at about 8 times the level in approved products. A vial that's stronger than its label is an unplanned dose increase. If you're weighing retatrutide for sale online, ask for a third-party lab report whose batch number matches your vial; without one, nobody can tell you how many milligrams are really in it.

Does the flat feeling go away?

No study has followed it, so there's no timeline to quote. Retatrutide's half-life is about 6 days, per the Phase 1b trial in The Lancet (see retatrutide half-life), so by our math about 20% is left 2 weeks after a last shot and about 4% after 4 weeks.

Online posts from people who stopped can't tell you how common either outcome is. The Phase 3 trials held each step for 4 weeks before going higher, and the page on how long retatrutide side effects last has the timelines that have actually been measured.

When mood changes need help

The FDA's advice for GLP-1 drugs fits retatrutide too: tell your doctor about new or worse depression, suicidal thoughts, or any unusual change in mood or behavior. NIMH says depression is diagnosed when symptoms last most of the day, nearly every day, for at least 2 weeks. If you've felt flat for 2 weeks, that's worth a proper conversation with your doctor before you change any dose yourself.

If you've had depression, bipolar disorder or a suicide attempt, tell your doctor before starting anything in this class, because the Phase 2 obesity trial, TRANSCEND-T2D-1 and both class analyses screened out at least some of those people. The wider safety record is on is retatrutide safe, and every other side effect is on the retatrutide side effects page.